文献速递临床试验与 GCP医学人工智能与信息学

无线观察治疗与直接观察治疗用于确认和支持结核病治疗依从性的随机对照试验

Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2019-10-04

本研究在77例药物敏感结核病继续期患者中评估无线观察治疗(WOT)的摄入检测准确性,并随机2:1比较WOT与直接观察治疗(DOT)确认的每日服药依从比例。WOT阳性检测准确率为99.3%(CI 98.1;100);意向治疗分析显示WOT确认93% vs DOT确认63%的每日处方剂量(p<0.001);去除周末、公共假日和停服药日后,WOT确认95.6% vs DOT确认92.7%(p=0.31),WOT非劣于DOT(差值2.8%,CI [-1.8%,9.1]);100%参与者偏好WOT,WOT相关不良事件<10%。

要点

  • WOT阳性检测准确率为99.3%(CI 98.1;100)。
  • 意向治疗分析中WOT确认93% vs DOT确认63%的每日处方剂量(p<0.001)。
  • 去除周末、公共假日和停服药日后WOT确认95.6% vs DOT确认92.7%(p=0.31),WOT非劣于DOT。

核心结论

  • 在准确性方面,WOT与DOT等效。
  • 在结核病治疗继续期,WOT在支持确认每日服药依从性方面优于DOT,且绝大多数参与者偏好WOT。
  • WOT应在高负担结核病环境中进行测试,可能对中低收入国家结核病规划提供实质性支持。

研究设计与样本

  • 研究评估了使用IS-enabled组合异烟肼150 mg/利福平300 mg(IS-Rifamate)的WOT在活动性结核分枝杆菌复合群病患者中的表现。
  • 77例药物敏感结核病继续期治疗患者,处方每日异烟肼300 mg和利福平600 mg,使用IS-Rifamate。
  • 参与者最初同时接受DOT和WOT 2-3周以计算WOT阳性检测准确率(PDA),95%CI采用bootstrap法以10,000个样本估计。
  • 61例参与者随后进入随机对照试验,按2:1随机分配接受WOT或最大化面对面DOT,比较WOT和DOT确认的处方剂量比例。
  • WOT组中若摄入未被远程确认,参与者在24小时内通过短信或电话联系以提供支持。

主要发现

  • WOT的PDA为99.3%(CI 98.1;100)。
  • 随机对照试验意向治疗分析显示,WOT确认93% vs DOT确认63%的每日处方剂量(p<0.001)。
  • 去除所有非工作日(周末和公共假日)和停服药日后的次要分析显示,WOT确认95.6% vs DOT确认92.7%(p=0.31);WOT非劣于DOT(差值2.8%,CI [-1.8%,9.1])。
  • 100%的参与者偏好使用WOT。
  • WOT相关不良事件<10%,包括与贴片相关的轻微皮疹和瘙痒。

临床怎么用

  • WOT提供近实时的纵向数字报告,支持患者自我管理,并允许快速远程识别需要更多支持以维持依从性者。
  • 作者认为WOT应在高负担结核病环境中进行测试,可能对中低收入国家结核病规划提供实质性支持。

局限性

  • 本研究在结核病治疗继续期进行,限制了其对整个结核病治疗疗程的普遍性。
  • 敏感性分析未在试验注册中预先指定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excellent adherence to tuberculosis (TB) treatment is critical to cure TB and avoid the emergence of resistance. Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions. Our study determined the accuracy of ingestion detection in clinical and home settings using WOT and subsequently compared, in a randomized control trial (RCT), confirmed daily adherence to medication in persons using WOT or directly observed therapy (DOT) during TB treatment. METHODS AND FINDINGS: We evaluated WOT in persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate). Seventy-seven participants with drug-susceptible TB in the continuation phase of treatment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate. The primary endpoints of the trial were determination of the positive detection accuracy (PDA) of WOT, defined as the percentage of ingestions detected by WOT administered under direct observation, and subsequently the proportion of prescribed doses confirmed by WOT compared to DOT. Initially participants received DOT and WOT simultaneously for 2-3 weeks to allow calculation of WOT PDA, and the 95% confidence interval (CI) was estimated using the bootstrap method with 10,000 samples. Sixty-one participants subsequently participated in an RCT to compare the proportion of prescribed doses confirmed by WOT and DOT. Participants were randomized 2:1 to receive WOT or maximal in-person DOT. In the WOT arm, if ingestions were not remotely confirmed, the participant was contacted within 24 hours by text or cell phone to provide support. The number of doses confirmed was collected, and nonparametric methods were used for group and individual comparisons to estimate the proportions of confirmed doses in each randomized arm with 95% CIs. Sensitivity analyses, not prespecified in the trial registration, were also performed, removing all nonworking (weekend and public holiday) and held-dose days. Participants, recruited from San Diego (SD) and Orange County (OC) Divisions of TB Control and Refugee Health, were 43.1 (range 18-80) years old, 57% male, 42% Asian, and 39% white with 49% Hispanic ethnicity. The PDA of WOT was 99.3% (CI 98.1; 100). Intent-to-treat (ITT) analysis within the RCT showed WOT confirmed 93% versus 63% DOT (p < 0.001) of daily doses prescribed. Secondary analysis removing all nonworking days (weekends and public holidays) and held doses from each arm showed WOT confirmed 95.6% versus 92.7% (p = 0.31); WOT was non-inferior to DOT (difference 2.8% CI [-1.8%, 9.1%]). One hundred percent of participants preferred using WOT. WOT associated adverse events were <10%, consisting of minor skin rash and pruritus associated with the patch. WOT provided longitudinal digital reporting in near real time, supporting patient self-management and allowing rapid remote identification of those who needed more support to maintain adherence. This study was conducted during the continuation phase of TB treatment, limiting its generalizability to the entire TB treatment course. CONCLUSIONS: In terms of accuracy, WOT was equivalent to DOT. WOT was superior to DOT in supporting confirmed daily adherence to TB medications during the continuation phase of TB treatment and was overwhelmingly preferred by participants. WOT should be tested in high-burden TB settings, where it may substantially support low- and middle-income country (LMIC) TB programs. TRIAL REGISTRATION: ClinicalTrials.gov NCT01960257.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019. PMID: 31584944. doi:10.1371/journal.pmed.1002891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。